Mandate

Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm

Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market.

The prospectus was published on 20 June 2018 and the trading on Nasdaq Stockholm commenced on 25 June 2018.
 
Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. 
 
Vinge’s team has primarily consisted of Dain Hård Nevonen, David Andersson, Maria Schultzberg, Nils Fredrik Dehlin, Malte Hedlund, Anna Thoms, Klara Secher and Victor Ericsson.

Related

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024

Vinge advises Sobro in connection with investment in Clinton Marine Survey

Clinton Marine Survey has chosen to broaden its ownership with Sobro as a new partner and majority shareholder. All existing owners remain as significant shareholders. Clinton Marine Survey offers high quality hydrographic and geological surveys for navigation, dredging operations, mapping, marine construction and more.
April 09, 2024

Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III

Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fund III. The fund closed successfully with commitments of approximately SEK 1.5 billion from an international investor base consisting of a number of leading financial institutions. The investor interest in the fund raising was very strong, and the fund was significantly oversubscribed.
April 05, 2024